Navigation Links
ASCO data highlight novel anti-cancer approach that exposes tumors to immune attack
Date:5/20/2010

TUSTIN, Calif., May 20, 2010 -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical-stage biopharmaceutical company developing innovative monoclonal antibodies for the treatment of cancer and viral infections, will present data from three Phase II clinical trials highlighting the clinical potential of its unique phosphatidylserine (PS)-targeting antibody bavituximab for the treatment of solid tumors. PS-targeting antibodies represent an entirely new approach to treating cancer, using a novel immunomodulatory mechanism that enables the patient's own immune system to attack and destroy the tumor. Phase II data on the company's lead PS-targeting antibody bavituximab administered in combination with chemotherapy will be presented at the 2010 ASCO Annual Meeting.

"PS is a highly immunosuppressive molecule that inactivates the immune system and allows tumors to evade detection," commented Dr. Philip Thorpe, professor of pharmacology at the University of Texas Southwestern Medical Center, a scientific advisor to Peregrine and a pioneer in the development of PS-targeting therapies. "Supported by a growing body of research, PS-targeting antibodies appear to play a critical role in blocking this immunosuppressive molecule and reactivating the immune system's ability to mount a robust anti-tumor response. Since chemotherapy increases the exposure of PS on tumor blood vessels, bavituximab has even more of this immunosuppressive molecule to target, potentially offering a new synergistic approach for the treatment of cancer."

Based on the positive data reported to date, Peregrine plans to initiate a new randomized, placebo-controlled, double-blinded Phase II trial of bavituximab in combination with chemotherapy in refractory non-small cell lung cancer (NSCLC) patients. A new Phase II trial in front-line NSCLC patients is also expected to begin in by mid-year.

Reactivating the Immune System by Blocking "Flipped" Phospholipids

Usually located on the inside of healthy cell membranes, PS "flips" and becomes exposed on the outside of cells that line tumor blood vessels. PS also becomes exposed on virus-infected cells and enveloped viruses. A growing body of scientific evidence shows that this exposed PS inactivates the body's normal immune response.

The "flipped" PS molecules therefore create a specific target for anti-cancer and anti-viral treatments, leaving healthy cells unaffected. Peregrine's PS-targeting antibodies such as bavituximab target and block this immunosuppressive PS target, enabling the immune system to recognize the cancer cells as foreign and to reactivate the immune system to attack the tumor and inhibit its growth.

Clinical Evidence Synergistic Mechanism of Action

Clinical evidence supporting the PS-targeting approach will be discussed in three sessions at the 2010 ASCO Annual Meeting. Prior clinical data show that in combination with chemotherapy in advanced breast and lung cancer patients, Peregrine's first-in-class antibody bavituximab has achieved objective tumor response rates that compare favorably with chemotherapy alone. Bavituximab has also demonstrated a promising safety profile.

Of special interest, these prior clinical data also suggest that the PS-targeting mechanism may have additive therapeutic effects with other cancer treatments. This builds on preclinical studies that have previously shown that a number of FDA-approved anti-cancer treatments up-regulate the PS exposed on the tumor vasculature. Numerous preclinical studies have also demonstrated enhanced anti-tumor effects of PS-targeting antibodies when used in combination with a range of standard anti-cancer treatments, including radiation, chemotherapy, hormone depletion therapy and most recently, agents that induce apoptosis.

ASCO posters reporting bavituximab Phase II clinical results include:

Saturday, June 5, 2010, 2:00 6:00 pm CT

Phase II study of bavituximab plus docetaxel in locally advanced or metastatic breast cancer (Abstract #1042), Author: David Tabagari, Poster Board 22C, S Hall A2

Phase II study of bavituximab plus paclitaxel and carboplatin in locally advanced or metastatic breast cancer: Interim results (Abstract #1062), Author: Minish Jain, Poster Board 22G, S Hall A2

Sunday, June 6, 2010, 8:00 12:00 pm CT

Phase II study of bavituximab plus paclitaxel and carboplatin in untreated locally advanced or metastatic non-small cell lung cancer: Interim results (Abstract #7589), Author: Raghunadharao Digumarti, Poster Board 40H, S Hall A2


'/>"/>

Contact: Barbara Lindheim
blindheim@biocompartners.com
212-918-4650
BioCom Partners
Source:Eurekalert

Related medicine news :

1. TCT for Surgeons course will highlight hybrid surgical and interventional techniques
2. Cancer health disparities research highlighted at AACR 101st Annual Meeting 2010
3. Health: Stem Cell Breakthrough Highlights Adult Stem Cell Promise Says Christian Drapeau
4. St. Vincent's Hospital Layoffs Highlight Need for WARN Notice and Remedies
5. Professional Members of Human Rights Organization Hold Press Conference to Highlight Government Invasion of Privacy
6. CCH Briefing Highlights Employer, Medicare Provisions of Health Care Reform Proposals
7. Special Session Highlights Late-Breaking Abstracts
8. DUSA Pharmaceuticals, Inc.(R) to Host Fourth Quarter and Full Year 2009 Financial Results and Corporate Highlights Conference Call
9. Registered Nurses from Public Health - Seattle & King County Hold Informational Picket to Highlight Public Safety Concerns
10. FDA Cancer Drug Approval Rate Highlighted in JNCI
11. New Lumension Webcast Highlights Key Steps to Prepare Healthcare Firms and Business Associates to Comply with New HITECH Act
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... (PRWEB) , ... February 12, 2016 , ... ... through a world of exterior design possibilities. CertainTeed, North America’s leading brand of ... by expanding the product offerings showcased in the mobile version of the ColorView® ...
(Date:2/12/2016)... ... ... Coast Autism Spectrum Center (CCASC) invites teens ages 11-18 to its annual Winter Teen Dance. ... and without special needs to gather in a safe and supportive environment. Volunteers will be ... place on Saturday, Feb. 13 from 7 to 9:30 p.m. at Elks Lodge, 322 Elks ...
(Date:2/12/2016)... ... 2016 , ... Planet Future is a Final Cut Pro X ... for showcasing pictures, videos as well as text in an exciting cartoon environment. Planet ... and a beautiful frame overlay. Pixel Film Studios makes editing easy; simply insert media ...
(Date:2/11/2016)... ... February 11, 2016 , ... “ HEALING MIND : ... Well Managed Mind” (published by Balboa Press) teaches readers how to become their own ... profound love, author Janice McDermott, M.Ed., LCSW, offers an understanding of how to heal ...
(Date:2/11/2016)... Jersey (PRWEB) , ... February 11, 2016 , ... Registered ... a free CEU seminar titled, “Stroke Management: Time to Act, Time to Heal” on ... Community in Whippany, N.J. The presenter is Vishal Chedda, president of ANSA Consultants, ...
Breaking Medicine News(10 mins):
(Date:2/11/2016)... IRVINE, Calif., Feb. 11, 2016 PRO-DEX, INC. (NasdaqCM: ... quarter ended December 31, 2015. The Company also filed its ... fiscal year 2016 with the Securities and Exchange Commission today. ... December 31, 2015 --> --> ... 2015 increased $2.6 million, or 95%, to $5.4 million from ...
(Date:2/11/2016)... has committed to provide drug disposal kiosks in ... as part of a program to combat drug ... organization As You Sow. Conrad MacKerron , Senior ... to unneeded drugs because they lack easily accessible collection and ... Conrad MacKerron , Senior Vice President at As You ...
(Date:2/11/2016)... -- Potrero Medical, Inc., the developer of the Accuryn™ critical ... George M. Rapier, III , MD, to its Board ... WellMed is one of the nation,s largest physician owned practice ... Texas and Florida ... internal medicine practice, he has been instrumental to the company,s ...
Breaking Medicine Technology: